title: [Pharmacological studies on alterations in myocardial beta-adrenoceptors and their intracellular signal transduction in experimental diabetic rats].
abstract: The present study was undertaken to determine abnormalities which are responsible for the diminished functional responsiveness to beta-adrenoceptor stimulation in experimental diabetic rats. Rats were given an intravenous injection of 45mg/kg streptozotocin and hearts were removed from 4 to 6 weeks later. The positive inotropic effects of isoproterenol, norepinephrine and epinephrine were markedly depressed in diabetic rat papillary muscles. Diabetic cardiac muscles also exhibited a reduced maximum contractile responses to forskolin, 3-isobutyl-1-methylxanthine and dibutylic cyclic AMP. The density of beta-adrenoceptors in membranes prepared from diabetic hearts was decreased by 40%, with uniform decreases in the beta 1- and beta 2-subtypes. The affinity of the receptor for the radioligand antagonist [125I]-iodocyanopindolol remained unchanged. Competition binding studies with isoproterenol did not reveal a difference in the fraction of beta-adrenoceptors with high-affinity binding between control and diabetic cardiac membranes, suggesting that interaction between beta-adrenoceptors and Gs may be preserved well in the diabetic state. All measures of adenylate cyclase activity showed that beta-adrenoceptor-dependent and Gs-dependent cyclic AMP productions are well maintained in membranes from diabetic hearts. Thus, these data suggest that the decreased positive inotropic response to beta-adrenoceptor stimulation in diabetic hearts is not attributable to changes in beta-adrenoceptor-Gs-adenylate cyclase system but rather may be due to an alteration in cellular function beyond the level of cAMP generation. To test this hypothesis, incorporation of [32P]-inorganic phosphate into phospholamban in sarcoplasmic reticulum was examined in Langendorff-perfused hearts. Isoproterenol (100nM) increased phosphorylation of phospholamban threefold in control hearts, but did not cause a significant change in the phosphorylation state in diabetic hearts. From these findings it is concluded that the decreased functional responses to cyclic AMP-increasing agents like beta-adrenoceptor agonists in diabetic hearts may be associated with impaired phosphorylation of cardiac regulatory phosphoproteins including phospholamban.
authors.affiliation: Department of Pharmacology, Hokkaido University School of Medicine, Sapporo, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Gando
mesh_terms: D000262:Adenylyl Cyclases / Q000378:metabolism; D000818:Animals; D002135:Calcium-Binding Proteins / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism / Q000503:physiopathology*; D066298:In Vitro Techniques; D007545:Isoproterenol / Q000494:pharmacology; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects; D009206:Myocardium / Q000378:metabolism*; D010766:Phosphorylation; D051381:Rats; D017208:Rats, Wistar; D011943:Receptors, Adrenergic, beta / Q000187:drug effects / Q000502:physiology*; D015398:Signal Transduction; D013268:Stimulation, Chemical; D013311:Streptozocin; D000099211:Phospholamban
chemical_list: D000262:Adenylyl Cyclases; D002135:Calcium-Binding Proteins; D007545:Isoproterenol; D011943:Receptors, Adrenergic, beta; D013311:Streptozocin; D000099211:Phospholamban